Galapagos NV develops medicines for oncology and immunology, primarily in the US and Europe. Their pipeline includes GLPG3667, GLPG5101, GLPG5201, and GLPG5301, all CAR-T product candidates. These products are in various stages of Phase 1/2 trials for different types of cancer. The company has collaboration agreements with Gilead Sciences and AbbVie.
| Indicator | Value |
|---|---|
| PER | 24.1 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 1.0 |